logo
Being fit is not an excuse to skip a health checkup. Here's why

Being fit is not an excuse to skip a health checkup. Here's why

Mint21-04-2025
Nine years ago, when I met him in his office for
a column in this very publication, Darshan Mehta,
then 55 and managing director of Reliance Brands, effortlessly jumped on to his desk and posed cross-legged for a picture. India Inc was well aware of his love of running and would regularly cite his example whenever they had to name someone who had built a successful career but also always made time for exercise, health and wellbeing. Very recently, the sexagenarian suffered a fatal heart attack while running on the treadmill. Jog the memory back four years and the dramatic heart attack that Danish footballer Christian Eriksen suffered on-field while playing a UEFA Euro Cup game comes to mind. Just 29 at the time, Eriksen was revived by doctors on the field, and was then moved to a hospital, as billions watched the whole thing unfold live on television.
Eriksen, among one of the fittest men in the world, and Mehta aren't the first healthy people to suffer heart attacks. It's just that thanks to social media, the internet and instant messaging, the word spreads faster today. While those who don't want to exercise may use this as a valid warning to avoid anything 'strenuous", thereby, putting themselves at a greater risk of developing health problems, fit and active people need to pay heed to these incidents and make health screenings a regular part of their lives.
Even people who appear extremely fit and active may have underlying health issues that are silent in the early stages, explains Dr Sandeep Doshi, consultant for internal medicine and executive health checkup, Kokilaben Dhirubhai Ambani Hospital, Mumbai. 'Conditions like high blood pressure, diabetes, kidney diseases, liver issues, or even certain cancers may show no symptoms initially but can still progress quietly," says Doshi.
In medical terms, a 'fit" person is someone who meets a set of baseline physical and clinical health indicators such as Body Mass Index (BMI) between 20-24, has normal results on electrocardiogram (ECG) and Stress Test (an indicator of heart function), shows normal range on basic laboratory tests, including parameters like blood sugar, cholesterol, kidney and liver function. Additionally, they should be able to walk at least 5km in an hour, which is the minimum threshold of cardiovascular and musculoskeletal fitness, say doctors and fitness experts. 'However, being fit does not always equate to being free of underlying health risks, which is why a deeper understanding of individual health status is important," warns Dr Narander Singla, lead consultant for internal medicine at the CK Birla Hospital, New Delhi.
Regular medical check-ups help detect underlying and dormant health issues when they are still treatable or manageable. 'Specifically, these check-ups should include blood pressure monitoring, blood sugar testing (fasting and post-meal), kidney function tests (serum creatinine, urea), liver function tests, cholesterol and lipid profile, ECG and/or Stress Test (Treadmill Test), ultrasound abdomen (to detect organ changes), screening for breast and cervical cancer for women, and screening for colon cancer as per age guidelines for both men and women. These tests form the foundation of preventive health and are key to identifying silent conditions early," says Doshi.
While Doshi says routine health check-ups should start at 40 years of age, Singla recommends starting earlier, between 20 and 30 years, and continuing for the rest of your life. Dr Udgeath Dhir, director and head of cardiothoracic and vascular surgery, Fortis Memorial Research Institute, Gurugram, suggests people should start even earlier. 'Hypertension and diabetes are silent killers. These illnesses start at a young age, so school and college students should also get their blood pressure checked regularly," says Dhir. However, all three unanimously agree that if someone has a family history of disease or heart condition these check-ups need to begin at a much earlier age.
'Individuals with a family history of chronic conditions such as diabetes, hypertension, heart disease, stroke, or cancer should be more vigilant. For them, starting check-ups earlier and more frequently (every three or six months) may be necessary to detect early warning signs and manage risks proactively," advises Singla. Doshi adds that people who smoke and who work in high-stress professions should also start check-ups earlier and more frequently. 'The frequency of the check-ups depends on the risk profile and previous findings, but annual evaluations are a common and effective benchmark for middle-aged and high-risk individuals," suggests Doshi.
As an elite footballer playing for a top tier European football club, Eriksen underwent extensive 'medicals" and testing regularly. Mehta had access to the best healthcare and testing facilities in India. While regular medical check-ups are comprehensive and can help detect most illnesses and risk factors early, some health issues, especially certain cardiovascular conditions, may not be evident even in routine tests. This is why we sometimes see professional athletes (like Eriksen) and fit individuals, who undergo extensive evaluations and have access to top-tier healthcare, still suffer sudden and severe health events like heart attacks, explains Singla.
'Contributing factors could include genetic predisposition, undiagnosed structural heart anomalies, stress, or even random and unpredictable biological events. This underscores the fact that health screenings reduce risk but cannot eliminate it entirely," adds Singla. Doshi flags another dilemma that doctors face: there is always a clinical challenge in determining how far to investigate someone with no symptoms or complaints. 'A coronary angiography is an excellent test to detect blockages in the heart arteries. But would you conduct this invasive test on a person who feels completely fine and has no symptoms? While testing is powerful, routine use of high-end diagnostic tools in healthy individuals is not always justified, unless specific risk factors are present. Moreover, some events cannot be predicted, even with the best tests and technology," argues Doshi.
For those who want to use untimely deaths of a few as a reason to not exercise, there is no greater disservice you can do to yourselves.
Exercise is the cornerstone of long-term health and disease prevention. Without regular physical activity all major body systems deteriorate over time, muscles weaken, blood vessels stiffen, metabolism slows, and immune responses decline, says Doshi. Exercise prepares the body for emergencies be it fighting infections, managing stress, or recovering from illness. It helps maintain proper levels of electrolytes, hormones, prostaglandins, interferons, and other important biochemical compounds that keep the body running smoothly. It also preserves the tone and strength of skeletal and cardiac muscles, and ensures healthy blood circulation through the effective functioning of venous valves.
Simply put, an active lifestyle reduces the risk of chronic diseases, improves quality of life, and increases longevity. At the same time, those who are already active and can finish a gruelling marathon with a smile, should avoid assuming invincibility and undergo medical check-ups as advised by their doctors. 'No matter how active one may be, it's important to be realistic about your body's changing capabilities with age. Just because someone could complete a marathon at 35, it doesn't mean they can or should attempt the same at 55 without proper reassessment and conditioning," notes Doshi.
Shrenik Avlani is a writer and editor and the co-author of The Shivfit Way, a book on functional fitness.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Finsen's Nobel-winning light therapy and its role in treating skin tuberculosis
Finsen's Nobel-winning light therapy and its role in treating skin tuberculosis

The Hindu

time2 days ago

  • The Hindu

Finsen's Nobel-winning light therapy and its role in treating skin tuberculosis

In 1903, Danish physician and scientist Niels Ryberg Finsen was awarded the Nobel Prize in Physiology or Medicine 'in recognition of his contribution to the treatment of diseases, especially lupus vulgaris, with concentrated light radiation.' Lupus vulgaris, a skin form of tuberculosis, was once treated with ultraviolet light therapy. In the late 1800s, Finsen discovered that concentrated UV light beams could inhibit bacterial growth, and he successfully used this treatment on patients. Although light therapy was widely used for a time, it eventually gave way to antibiotics. His groundbreaking work marked one of the earliest uses of a physical force --light as a therapeutic tool, and laid the foundation for what we now call phototherapy. Personal health struggles and research Finsen's scientific journey was inseparable from his personal health struggles. Born on December 15, 1860, in Tórshavn, in the Faroe Islands, then a remote territory of the Danish Kingdom, Finsen grew up in a family of educators and administrators. As a child, he showed academic promise, but his health was often precarious. By early adulthood, he began showing signs of a debilitating illness, now believed to be Niemann–Pick disease, a rare genetic condition affecting lipid metabolism. The disease caused chronic fatigue, abdominal swelling, and progressive physical decline, eventually leaving him largely immobile. Unable to pursue a traditional clinical career due to his worsening condition, Finsen turned toward research. His own body became, in part, a source of inspiration. He noticed that exposure to sunlight offered some temporary relief from his symptoms and became curious about how light interacted with human tissue. This curiosity became a lifelong focus and would eventually transform medical treatment for a highly stigmatised disease of the time: lupus vulgaris, or cutaneous tuberculosis. In the 1890s, lupus vulgaris was one of the most persistent and disfiguring manifestations of tuberculosis, which was then a leading cause of death worldwide. The skin form of TB caused ulcerating lesions, often on the face, which led to long-term deformity, particularly in young patients. At the time, there was no reliable or humane treatment. Finsen hypothesised that light --specifically the chemical rays in the blue and ultraviolet spectrum could act directly on the bacteria and stimulate healing of the infected tissue. Working initially with filtered sunlight, Finsen designed techniques to remove the heat-producing infrared rays and concentrate the short-wavelength radiation. As his understanding deepened, he transitioned to using carbon arc lamps, which allowed for controlled, high-intensity delivery of light even in low-sunlight conditions. In 1896, with support from the Danish government and scientific community, he founded the Finsen Medical Light Institute in Copenhagen. There, with a small team of physicians and nurses, he treated more than 1,000 patients suffering from lupus vulgaris over the next few years. Phototherapy, the Nobel prize and global health impact What set Finsen's work apart was its methodological rigour and reproducibility. His technique focused light beams onto the lesions for extended periods, often hours, under precise protocols. Patients experienced significant reduction in inflammation, healing of open lesions, and most importantly an arrest in disease progression. Many were children who had exhausted all other options. His clinical success offered proof that light could be used as medicine, a revolutionary idea in a period when most therapies were either surgical or pharmacological. But Finsen's contributions were not only practical, they were conceptual breakthroughs. He was among the first to propose that external physical forces, not just chemicals or immune stimulation, could be harnessed in disease management. His ideas inspired future therapies including ultraviolet sterilisation, photodynamic therapy for certain cancers, and the now-routine phototherapy for neonatal jaundice. Despite the growing recognition, Finsen's personal health deteriorated. By the early 1900s, he was unable to walk and conducted most of his work from bed, often dictating to assistants. Yet he continued to publish, consult, and treat patients until the end of his life. His declining health added urgency and poignancy to his scientific mission, and he became a symbol of resilience in the medical and public health communities across Europe. His recognition by the Nobel Committee in 1903 was significant not just for its scientific merit but for the humanitarian impact of his work. Finsen was the third person to receive the Nobel Prize in Physiology or Medicine, following Emil von Behring and Ronald Ross. His award highlighted the growing international consensus that medicine must not only advance knowledge but reduce suffering in real and measurable ways. Tragically, Finsen's own health issues prevented him from attending the Nobel Prize ceremony. His legacy today Finsen passed away the following year, in September 1904, at the age of just 43. His work outlived him. In the decades that followed, the Finsen lamp and its modified versions were used in hospitals throughout Europe and North America. The principles he established continue to influence treatment today. Phototherapy is now a standard of care in dermatology for conditions like psoriasis, vitiligo, and eczema, and it is also used in oncology, ophthalmology and neonatology. Modern techniques such as narrowband UVB, laser therapies and blue light for acne all owe conceptual debts to Finsen. Even in infection control, ultraviolet germicidal irradiation -- now widely adopted in healthcare and public spaces -- rests on the same light-tissue interaction theories Finsen helped establish. While the World Health Organization (WHO)does not name Finsen individually, its clinical guidelines for treating neonatal jaundice recommend phototherapy as a first-line, life-saving intervention. The global adoption of this therapy, especially in low- and middle-income countries, reflects Finsen's enduring influence. Today, the Finsen Institute remains part of Copenhagen University Hospital. His former residence and laboratory have been preserved as historical landmarks. Statues and memorials in Denmark honour him not as a scientist who worked quietly, under immense personal strain, to expand the frontiers of medicine.

Cipla to enter weight management segment in India: MD & Global CEO Vohra
Cipla to enter weight management segment in India: MD & Global CEO Vohra

Business Standard

time2 days ago

  • Business Standard

Cipla to enter weight management segment in India: MD & Global CEO Vohra

Drug major Cipla is preparing to foray into the weight management segment in India, its MD and global CEO Umang Vohra has said. The Mumbai-based firm is also strengthening its presence in the central nervous system (CNS) therapeutic area, he stated in his address to shareholders in the company's Annual Report for 2024-25. "Our efforts are rooted in understanding patient needs, reducing stigma, and delivering differentiated therapies for niche is emerging as a priority area for Cipla. With a clear strategic intent, we are preparing to enter the weight management segment in India, aiming to address the rising demand for effective obesity solutions," Vohra stated. Several domestic drug firms are developing drugs for weight loss to capitalise on the growing market for obesity and diabetes management. US drugmaker Eli Lilly & Co has already launched its anti-obesity drug Mounjaro in the country. Danish firm Novo Nordisk has also launched its anti-obesity drug Wegovy, indicated for both long-term chronic weight management and reduction in risk of major adverse cardiovascular events. In the CNS segment, Cipla has successfully in-licensed Sanofi's India CNS product range, including Frisium, a leading brand in the anti-epileptic category, Vohra informed shareholders. "Building on this momentum, we aim to pursue similar in-licensing deals or acquisitions in niche indications of attention deficit hyperactivity disorder (ADHD) and Parkinson's disease," he said. The company is equally committed to addressing the global crisis of antimicrobial resistance (AMR), he added. "Our AMR portfolio is evolving from volume-based to innovation-led, with four novel products in development," Vohra said. He noted that the company's ambition is to be a global, innovation-led, patient-centric healthcare company that creates long-term value through science, empathy, and sustainability. "We will continue to invest in big brands, strategic alliances, digital infrastructure, and next-generation therapies, while remaining rooted in our founding values of care and compassion," Vohra stated. Cipla's consolidated revenue stood at Rs 27,548 crore in FY25. Its consolidated net profit rose to Rs 5,272 crore during the period.

Cipla eyes entry into India's weight management market amid rising demand and global competition
Cipla eyes entry into India's weight management market amid rising demand and global competition

Time of India

time2 days ago

  • Time of India

Cipla eyes entry into India's weight management market amid rising demand and global competition

Drug major Cipla is preparing to foray into the weight management segment in India, its MD and global CEO Umang Vohra has said. The Mumbai-based firm is also strengthening its presence in the central nervous system (CNS) therapeutic area, he stated in his address to shareholders in the company's Annual Report for 2024-25. "Our efforts are rooted in understanding patient needs, reducing stigma, and delivering differentiated therapies for niche is emerging as a priority area for Cipla. With a clear strategic intent, we are preparing to enter the weight management segment in India, aiming to address the rising demand for effective obesity solutions," Vohra stated. Several domestic drug firms are developing drugs for weight loss to capitalise on the growing market for obesity and diabetes management. US drugmaker Eli Lilly & Co has already launched its anti-obesity drug Mounjaro in the country. Live Events Danish firm Novo Nordisk has also launched its anti-obesity drug Wegovy, indicated for both long-term chronic weight management and reduction in risk of major adverse cardiovascular events. In the CNS segment, Cipla has successfully in-licensed Sanofi's India CNS product range, including Frisium, a leading brand in the anti-epileptic category, Vohra informed shareholders. "Building on this momentum, we aim to pursue similar in-licensing deals or acquisitions in niche indications of attention deficit hyperactivity disorder (ADHD) and Parkinson's disease," he said. The company is equally committed to addressing the global crisis of antimicrobial resistance (AMR), he added. "Our AMR portfolio is evolving from volume-based to innovation-led, with four novel products in development," Vohra said. He noted that the company's ambition is to be a global, innovation-led, patient-centric healthcare company that creates long-term value through science, empathy, and sustainability. "We will continue to invest in big brands, strategic alliances, digital infrastructure, and next-generation therapies, while remaining rooted in our founding values of care and compassion," Vohra stated. Cipla's consolidated revenue stood at Rs 27,548 crore in FY25. Its consolidated net profit rose to Rs 5,272 crore during the period.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store